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of Schistosomiasis in children 
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Abstract 
Background: Praziquantel (PZQ) is currently the drug of choice in treatment of Schistosomiasis 
because of its high efficacy, few and transient side effects, simple administration and competitive 
cost. In community-based management and during mass chemotherapy of Schistosomiasis, WHO 
recommended a dose pole where height is taken as a single parameter to select the required dose.  
Objective: To compare PZQ dose according to WHO dose pole with the calculated weight-
dependent dose and test their consistency. 
Method:  We used a growth percentile ruler (MOSWAR) that includes weight, height, head 
circumference and body surface area according to age and sex. Data were then compiled into a 
table-form that included PZQ dose according to the dose pole and the calculated mean weight-
dependent dose. 
Results:   The results showed that PZQ dose according to the dose pole is not consistent with the 
weight-dependent dose. 
Conclusion: During mass chemotherapy and community-based management of Schistosomiasis in 
children, we recommend the use of a similar table or a device similar to (MOSWAR) to determine 
PZQ dose according to whichever of the growth parameters is available. 
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he World Health Organization (WHO) 
estimated that 200 million people are 
infected with Schistosomiasis and 600 
million are at risk of infection in 76 countries. 
Recently, at risk population has been updated 
to 779 million1. Many of those with 
Schistosomiasis are in the Sub-Saharan 
Africa. It is estimated that 14 million 
preschool children in this region are infected 
with s. haematobium and 4.6 million with s. 
mansoni2. In Ghana, a parasitological 
prevalence of 11.2% for s. haematobium in 
infants of four months is now documented3, 
while in Uganda, it is reported that nearly 
50% of children under- three years of age 
living along the northern shoreline of Lake 
Victoria had s .mansoni infection4. In Niger, 
infection rates of s. haematobium in young 
children and their mothers are reported to be 
60.5% and 72.2% respectively5. Taking into 
consideration that in community-based 
management of Schistosomiasis and  
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during mass treatment campaigns, it is not 
always possible to have durable and 
efficacious weighing scales to apply weight-
dependent doses, WHO recommended a dose 
pole for Praziquantel (PZQ), as a primary 
agent in treatment of Schistosomiasis, that 
uses height as a single parameter to calculate 
the dose of PZQ with the lowest height 
division of 94 cm for a dose of one tablet (600 
mg) and a highest division of ≥178 cm for a 
dose of five tablets6. This dose pole did not 
consider children with growth faltering, short 
stature due to high prevalence of malnutrition 
or other debilitating chronic diseases and tall 
stature secondary to ethnic variations within 
the same region. Furthermore, it was observed 
that there is a treatment gap in the use of PZQ 
for treatment of Schistosomiasis since most of 
the previous studies included children more 
than six years old and adults7. This gap 
included children younger than 6 years who 
are indirectly exposed to infection by using 
contaminated water for bathing or washing 
cloths of infected children in pools and 
canals. Consequently, in recent studies done 
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in Uganda, the dose pole was  amended to 
accommodate for younger age groups i.e. less 
than   five years old and  it was suggested that 
WHO lower limit for a dose of one tablet is to 
be adjusted to >99 cm – 110 cm instead of the 
previous one of 94 cm. The extended dose 
pole added two new height intervals: 60 – 
84cm for one half of a tablet and >84 – 99cm 
for three quarters of a tablet8. 
Our study is planned to compare PZQ height-
dependent dose according to the WHO 
extended pole (60 -178cm) with the weight – 
dependent dose (40mg/kg body weight) and 
assess their consistency. 
Methodology 
For exploring  the validity of PZQ dose by 
comparing the extended WHO dose pole (60 
– 178cm) and weight-dependent dose 
(40mg/kg body weight), we used a handy, 
durable and easy to use growth percentile 
ruler that includes World Health 
Organization/National Center for Health 
Statistics –U.S.A records of weight and height 
according to age and sex. The ruler (MOSWAR) 
contains age for children from birth to 18 
years and gender on two different faces 
(Fig.1).  
 
Fig.1: MOSWAR growth percentile ruler (pink: 
girls, blue: boys) 
 
A sliding transparent window, when moved 
up and down the ruler, locates weight, height, 
head circumference and body surface area for 
the selected age with the 3rd, 50th and 97th 
percentiles apparent along three horizontal 
lines within the transparent window.  Weight 
of children is determined by using the data 
shown     on      (MOSWAR)     according   to  the  
corresponding height selected from the dose 
pole. All data were then transformed into a 
table form (Table 1) that included WHO dose 
pole and the corresponding age, weight and 
height as seen on (MOSWAR). Height-
dependent dose according to WHO dose pole, 
the calculated mean weight-dependent dose 
(Mean = ∑÷ n) and the calculated difference 
between the height-dependent dose and the 
mean weight-dependent dose are shown in 
different columns.   
Results 
Our results showed that PZQ dose when 
given according to the dose pole at the age 
group <5 years is less than the weight-
dependent dose. At age group >5 – 8 years 
and age group >12 -18 years it is almost equal 
to the weight-dependent dose while at age 
group 8 – 12 years and age ≥18 years it is 
more than the weight –dependent dose. 
Discussion 
The results of this study shows that PZQ dose 
when given according to the WHO dose pole 
is not consistent with the dose when 
calculated according to body weight. These 
results are compatible with the reports from 
Uganda where they noted that height is not a 
very adequate tool to determine the standard 
PZQ dose and that there was a significant 
difference in each dosing category when 
height instead of weight is used as a dosing 
tool, possibly due to the high prevalence of 
malnutrition that leads to growth retardation. 
Gender and ethnic variations should also be 
considered in this context. In addition, it is 
always difficult to assess length and height in 
children <5 years without having proper 
scales i.e. Infantometer or stadiometer 
respectively and well trained staff. At age ≥18 
years, growth velocity decelerates and the 
body surface area is affected by weight rather 
than height changes since it is the muscle 
mass and body fat that changes at this age 
group rather than height, hence height alone 
might not be a dependable parameter to 
estimate PZQ dose. Dose preparation and 
administration, using the currently available 
tablets of 600mg is rather inaccurate and 
cumbersome. 
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Table 1: Praziquantel dose/ height (WHO dose pole) Compared to dose/ weight (40mg/kg) 
 
 
Dose Pole (cm) Dose/Ht (mg) Corresponding Age Corresponding 
Weight (kg) 
Dose/Wt (mg) Mean Dose / 
Wt (mg)
Difference between 





60-84 ½ tab (300) 3 months - 1½ yr 5.6 – 11.5 224 - 460 342 42 ↓ 
>84-99 ¾ tab (450) >1½ yr - 3½ yr >11.5 – 15.3 460 - 612 536 86 ↓ 
>99-110 1 tab (600) >3½ yr – 5 yr >15.3 – 18.4 612 - 736 674 74 ↓ 
>110-124 1½ tabs (900) >5 yr – 8 yr >18.4 – 25.3 736 -1012 874 26 ≈ = 
125-137 2 tabs (1200) >8 yr – 10 yr >25.3 – 31.4 1012 - 1256 1134 66 ↑ 
138-149 2 ½ tabs (1500) >10 yr – 12 yr >31.4 – 39.8 1256 – 1592 1428 72 ↑ 
150-159 3 tabs (1800) >12yr – 14 yr >39.8 – 50.8 1592 – 2032 1812 12 ≈ = 
160-177 4 tabs (2400) >14 yr – 18 yr >50.8 – 68.9 2032 - 2756 2394 4 ≈ = 
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The required dose should be prepared by 
breaking the tablets into small pieces or by 
crushing it and adding to it a honey-based 
solution or a sweet drink to make palatable 
for children to drink. Furthermore, it is 
impractical to use weight alone as a single 
parameter to calculate PZQ dose since 
weighing scales are not always available in 
peripheral areas and they need regular 
maintenance and calibration. The table shown 
above and the growth percentile ruler that 
includes weight and height of children at 
different ages and sex are practical tools that 
can be used in health settings and mass 
chemotherapy campaigns until an efficient 
and cost-effective PZQ syrup formulation 
with long shelf-life is produced or an age 




PZQ is a safe, efficient and cost-effective 
drug when used in treatment of 
Schistosomiasis during mass chemotherapy 
campaigns or in treatment of isolated patients. 
Data derived from this study indicate that 
PZQ dose when used according to the 
suggested dose pole is not consistent with the 
dose calculated according to weight. We 
recommend a chart similar to the table that we 
used or a handy ruler that includes weight and 
height of children at different ages and sex to 
be used in community research work and 
during mass treatment campaigns to 
determine PZQ weight-dependent dose 
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